ADVANCED OR METASTATIC SOLID TUMORS

This is an early-stage study testing a new drug called PRTH-101, given alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors. The main goals are to find a safe dose, see how the body processes the drug, and check for any early…

This is the first study in people to test the safety and dosing of a new immunotherapy drug called PMC-309. It is for adults with advanced or metastatic solid tumors that have progressed despite prior treatments, including other immunotherapies. The study will test PMC-309 by its…

This is the first study in people testing a new cancer drug called HM16390. Researchers want to find the safest and most effective dose, both by itself and combined with an existing immunotherapy drug (pembrolizumab). The trial will enroll 292 adults with advanced or metastatic s…

This is the first study in humans testing a new drug called IPH4502 for people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to find a safe dose and see how well the body handles the drug. Researchers will also check for early signs t…

This is the first study in humans testing a new drug called KK2260 for people with advanced or spreading solid tumors. Researchers will first determine the safest dose and then test it in patients with specific cancers like esophageal and head/neck cancer. The main goals are to c…

This early-stage study is testing the safety of a new cancer drug called KGX101, both alone and combined with another drug called envafolimab. The trial involves 57 Chinese patients with advanced or metastatic solid tumors that haven't responded to standard treatments. Researcher…

This is the first human study testing a new cancer drug called BH3120, both alone and combined with an existing immunotherapy drug (pembrolizumab). The trial aims to find safe doses and see if the treatment helps control advanced solid tumors that have spread or can't be removed …

This study is testing a new drug called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 is designed to help the body's immune system fight cancer by targeting specific cells inside tumors that weaken the immune response. The m…

This early-stage study is testing a new drug called IDE161, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have spread. The main goals are to find safe doses and see if the treatment shows early signs of shrinkin…

This study is testing a new oral drug called ETX-19477 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can help control the cancer. Researchers are especially interested in enroll…

This is the first human study of LNCB74, a new targeted cancer drug designed to deliver chemotherapy directly to cancer cells. Researchers will test different doses in 145 adults with advanced solid tumors (including ovarian, breast, lung, and other cancers) to find the safest an…

This is the first study in people testing a new experimental drug called DAY301 for advanced cancers that have spread. Researchers will give increasing doses to about 254 patients with specific advanced solid tumors to find the safest dose and see if the drug shows early signs of…

This early-stage study is testing the safety and initial effects of a new oral medicine, PF-07799544, when taken with another drug, PF-07799933. It is for adults with advanced solid tumors, like melanoma or lung cancer, that have a specific genetic change called a BRAF V600 mutat…